MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Clinical trials for MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE explained in plain language.
Never miss a new study
Get alerted when new MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE trials appear
Sign up with your email to follow new studies for MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with Crohn's: drug trial targets remission
Disease control Recruiting nowThis phase 3 trial tests a drug called afimkibart in 100 children aged 2-17 with moderate-to-severe Crohn's disease. The goal is to see if it can help children feel better and heal their intestines. Participants will receive the drug as an IV infusion or injection, and researcher…
Matched conditions: MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for Crohn's sufferers: phase 3 drug trial launches
Disease control Recruiting nowThis study tests a new drug called RO7790121 (Afimkibart) in people with moderate-to-severe Crohn's disease. The goal is to see if the drug can reduce symptoms and heal the gut lining better than a placebo. About 425 adults who have not responded well to other treatments will tak…
Matched conditions: MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for Crohn's: phase 3 trial of afimkibart launches
Disease control Recruiting nowThis phase 3 study tests a drug called afimkibart in 600 people with moderate-to-severe Crohn's disease. Participants receive either the drug or a placebo to see if it can reduce symptoms and gut inflammation. The trial is double-blind, meaning neither patients nor doctors know w…
Matched conditions: MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC